Pioglitazone for Heroin and for Nicotine Dependence

Phase 1/2 Terminated 82 enrolled New York State Psychiatric Institute National Institute on Drug Abuse (NIDA) · collab Omeros Corporation · collab

RandomizedParallel-groupTriple-blindBasic science

Summary

The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy. Specifically, pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be used as an adjunct to agonist-based treatment.

Timeline

Start: 2011-03
Primary completion: 2014-04
Completion: 2014-06

Publications

Martinez S, Jones JD, Vadhan NP, Brandt L, Comer SD, Bisaga A. The acute and repeated effects of cigarette smoking and smoking-related cues on impulsivity. Drug Alcohol Rev. 2021 Jul;40(5):864-868. doi: 10.1111/dar.13206. Epub 2020 Nov 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pioglitazone	Small molecule	15 mg	—
Subject	Pioglitazone	Small molecule	45 mg	—

Pioglitazone for Heroin and for Nicotine Dependence

Summary

Timeline

Publications

Drugs

Indications